BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Diagnosis
131 results:

  • 1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
    Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
    Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Molecular complexity of intraductal carcinoma of the prostate.
    Zhu S; Xu N; Zeng H
    Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. New Molecular Markers for prostate cancer diagnosis.
    Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
    Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
    Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential.
    Ragavi R; Muthukumaran P; Nandagopal S; Ahirwar DK; Tomo S; Misra S; Guerriero G; Shukla KK
    Urol Oncol; 2023 Aug; 41(8):340-353. PubMed ID: 37032230
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Differences in prostate cancer Transcriptomes by Age at diagnosis: Are Primary Tumors from Older Men Inherently Different?
    Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
    Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With prostate cancer.
    Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
    JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Urinary biomarkers in the diagnosis of prostate cancer.].
    Ballesteros Ruiz C; Álvarez-Maestro M; Aguilera Bazán A; Martínez-Piñeiro L
    Arch Esp Urol; 2022 Mar; 75(2):165-172. PubMed ID: 35332886
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Association Between Androgen Deprivation Therapy and Mortality Among Patients With prostate cancer and COVID-19.
    Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
    JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Yamoah K; Asamoah FA; Abrahams AOD; Awasthi S; Mensah JE; Dhillon J; Mahal BA; Gueye SM; Jalloh M; Farahani SJ; Lal P; Rebbeck TR; Yarney J
    Prostate; 2021 Dec; 81(16):1402-1410. PubMed ID: 34529278
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
    Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
    Bell PD; Huber AR; Agostini-Vulaj D
    Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Liquid biomarkers in active surveillance.
    Dall'Era M
    World J Urol; 2022 Jan; 40(1):21-26. PubMed ID: 33590279
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings.
    Lau HD; Clark M
    Diagn Cytopathol; 2020 Dec; 48(12):E14-E17. PubMed ID: 32628337
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
    Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
    Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
    Chan E; Garg K; Stohr BA
    Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.